Mannatech (MTEX) Competitors $7.95 -0.36 (-4.33%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. IMUX, GNTA, VNRX, ANEB, PYXS, ADAP, PYRGF, VRCA, CNTB, and STROShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Immunic (IMUX), Genenta Science (GNTA), VolitionRx (VNRX), Anebulo Pharmaceuticals (ANEB), Pyxis Oncology (PYXS), Adaptimmune Therapeutics (ADAP), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Connect Biopharma (CNTB), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Its Competitors Immunic Genenta Science VolitionRx Anebulo Pharmaceuticals Pyxis Oncology Adaptimmune Therapeutics PyroGenesis Canada Verrica Pharmaceuticals Connect Biopharma Sutro Biopharma Immunic (NASDAQ:IMUX) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation. Is IMUX or MTEX more profitable? Immunic has a net margin of 0.00% compared to Mannatech's net margin of -0.19%. Mannatech's return on equity of -2.56% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -326.95% -181.34% Mannatech -0.19%-2.56%-0.57% Does the media favor IMUX or MTEX? In the previous week, Immunic had 1 more articles in the media than Mannatech. MarketBeat recorded 2 mentions for Immunic and 1 mentions for Mannatech. Mannatech's average media sentiment score of 1.87 beat Immunic's score of 0.47 indicating that Mannatech is being referred to more favorably in the news media. Company Overall Sentiment Immunic Neutral Mannatech Very Positive Which has higher valuation & earnings, IMUX or MTEX? Mannatech has higher revenue and earnings than Immunic. Mannatech is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$100.51M-$1.23-0.70Mannatech$115.04M0.13$2.49M-$0.10-79.50 Do institutionals & insiders hold more shares of IMUX or MTEX? 51.8% of Immunic shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 4.6% of Immunic shares are held by insiders. Comparatively, 41.5% of Mannatech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer IMUX or MTEX? Immunic currently has a consensus target price of $7.50, suggesting a potential upside of 768.06%. Given Immunic's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunic is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, IMUX or MTEX? Immunic has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. SummaryImmunic beats Mannatech on 9 of the 16 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.11M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-79.509.1628.6119.64Price / Sales0.13735.94437.49188.30Price / Cash3.89164.3436.0257.93Price / Book1.744.688.185.63Net Income$2.49M$30.99M$3.23B$257.73M7 Day Performance-7.72%0.57%-0.25%0.07%1 Month Performance-12.88%7.91%5.40%8.32%1 Year Performance13.09%-5.94%26.35%13.78% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech1.3706 of 5 stars$7.95-4.3%N/A+14.8%$15.11M$115.04M-79.50250Positive NewsGap DownIMUXImmunic2.4827 of 5 stars$0.77+5.2%$11.60+1,416.3%-38.7%$69.68MN/A-0.6270GNTAGenenta Science2.6015 of 5 stars$3.98+4.7%$25.00+528.1%+10.0%$69.50MN/A0.007Positive NewsGap DownVNRXVolitionRx2.0985 of 5 stars$0.67-9.0%$3.50+419.8%-1.0%$69.38M$1.31M-1.8780News CoverageGap UpANEBAnebulo Pharmaceuticals2.7155 of 5 stars$1.65-2.1%$5.50+234.3%-35.1%$69.02MN/A-6.334Positive NewsGap UpHigh Trading VolumePYXSPyxis Oncology2.1114 of 5 stars$1.14+3.6%$9.00+689.5%-63.8%$68.14MN/A-0.7260ADAPAdaptimmune Therapeutics1.7888 of 5 stars$0.24-3.6%$1.35+460.6%-78.1%$66.26M$178.03M-0.89490PYRGFPyroGenesis Canada0.0871 of 5 stars$0.35+4.0%N/A-53.5%$66.16M$9.14M-5.9190News CoverageGap UpVRCAVerrica Pharmaceuticals4.4536 of 5 stars$0.83+17.4%$8.00+863.9%-90.5%$65.36M$7.57M-0.6940CNTBConnect Biopharma3.0903 of 5 stars$1.14-2.5%$7.00+514.0%+15.9%$64.97M$26.03M0.00110Gap UpSTROSutro Biopharma4.2681 of 5 stars$0.74-2.9%$6.11+725.4%-82.2%$64.46M$62.04M-0.25240 Related Companies and Tools Related Companies IMUX Alternatives GNTA Alternatives VNRX Alternatives ANEB Alternatives PYXS Alternatives ADAP Alternatives PYRGF Alternatives VRCA Alternatives CNTB Alternatives STRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
